Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry.
Nguyen Y, Stirnemann J, Lautredoux F, Cador B, Bengherbia M, Yousfi K, Hamroun D, Astudillo L, Billette de Villemeur T, Brassier A, Camou F, Dalbies F, Dobbelaere D, Gaches F, Leguy-Seguin V, Masseau A, Pers YM, Pichard S, Serratrice C, Berger MG, Fantin B, Belmatoug N, On Behalf Of The French Evaluation Of Gaucher Disease Treatment Committee. Nguyen Y, et al. Among authors: bengherbia m. Int J Mol Sci. 2020 Feb 13;21(4):1247. doi: 10.3390/ijms21041247. Int J Mol Sci. 2020. PMID: 32069933 Free PMC article.
Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.
Serratrice C, Bengherbia M, Alessandrini M, Grosbois B, Camou F, Pers YM, Bismuth M, Marie I, Belmatoug N, Berger M; Comité d'Evaluation et de Traitement de la maladie de Gaucher. Serratrice C, et al. Among authors: bengherbia m. Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):94-6. doi: 10.1016/j.bcmd.2013.12.004. Epub 2014 Jan 7. Blood Cells Mol Dis. 2014. PMID: 24411065 No abstract available.
Prevalence of autoantibodies in the course of Gaucher disease type 1: A multicenter study comparing Gaucher disease patients to healthy subjects.
Serratrice C, Bensalah N, Penaranda G, Bardin N, Belmatoug N, Masseau A, Rose C, Lidove O, Camou F, Maillot F, Leguy V, Magy-Bertrand N, Marie I, Cherin P, Bengherbia M, Carballo S, Boucraut J, Serratrice J, Berger M, Verrot D. Serratrice C, et al. Among authors: bengherbia m. Joint Bone Spine. 2018 Jan;85(1):71-77. doi: 10.1016/j.jbspin.2016.12.002. Epub 2016 Dec 26. Joint Bone Spine. 2018. PMID: 28034821
Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.
Berger J, Vigan M, Pereira B, Nguyen TT, Froissart R, Belmatoug N, Dalbiès F, Masseau A, Rose C, Serratrice C, Pers YM, Bertchansky I, Camou F, Bengherbia M, Bourgne C, Caillaud C, Pettazzoni M, Berrahal A, Stirnemann J, Mentré F, Berger MG. Berger J, et al. Among authors: bengherbia m. Clin Pharmacokinet. 2019 Apr;58(4):469-482. doi: 10.1007/s40262-018-0708-8. Clin Pharmacokinet. 2019. PMID: 30128966 Clinical Trial.
A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher Disease.
Serratrice C, Stirnemann J, Berrahal A, Belmatoug N, Camou F, Caillaud C, Billette de Villemeur T, Dalbies F, Cador B, Froissart R, Masseau A, Brassier A, Hivert B, Swiader L, Bertchansky I, de Moreuil C, Chabrol B, Durieu I, Leguy Seguin V, Astudillo L, Humbert S, Pichard S, Marcel C, Hau Rainsard I, Bengherbia M, Yousfi K, Berger MG. Serratrice C, et al. Among authors: bengherbia m. J Clin Med. 2020 Jul 22;9(8):2343. doi: 10.3390/jcm9082343. J Clin Med. 2020. PMID: 32708003 Free PMC article.